Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03126812
Title Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD


No variant requirements are available.